Plain-English translation of NCT04382846 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether a medication called can help treat COVID-19 when combined with standard medical care. has shown promise in laboratory and early clinical studies against viruses similar to the one that causes COVID-19. Researchers want to see if adding this medication to usual treatment helps patients recover better.
COVID-19 is a serious illness, and doctors are looking for additional treatment options beyond standard care to help patients recover faster and more completely. Early evidence suggests this medication may have antiviral properties, but it needs to be carefully tested in a larger group of patients to confirm it works safely and effectively.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will either receive the medication along with standard COVID-19 treatment, or standard treatment alone. The study is comparing how well people do with and without the medication added to their care. You will be monitored by the research team to track your recovery and any side effects.
AI-generated summary from trial data · Jun 26, 2026 · Not medical advice
Egypt
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.